Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.
![Prime Medicine logo](/files/LOGO/1894562-PRME.png)
Company profile
Ticker
PRME
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PRME stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
12 Jun 24
DEFA14A
Additional proxy soliciting materials
21 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
10 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
S-8
Registration of securities for employees
1 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 107.66 mm | 107.66 mm | 107.66 mm | 107.66 mm | 107.66 mm | 107.66 mm |
Cash burn (monthly) | (no burn) | 3.28 mm | 16.11 mm | 17.76 mm | 22.57 mm | 15.96 mm |
Cash used (since last report) | n/a | 12.66 mm | 62.30 mm | 68.66 mm | 87.27 mm | 61.72 mm |
Cash remaining | n/a | 94.99 mm | 45.35 mm | 38.99 mm | 20.39 mm | 45.93 mm |
Runway (months of cash) | n/a | 29.0 | 2.8 | 2.2 | 0.9 | 2.9 |
Institutional ownership, Q1 2024
81.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 115 |
Opened positions | 56 |
Closed positions | 15 |
Increased positions | 25 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 411.71 bn |
Total shares | 98.27 mm |
Total puts | 66.30 k |
Total calls | 57.70 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
GOOG Alphabet Inc - Ordinary Shares | 15.06 mm | $105.44 bn |
GV 2019 | 15.06 mm | $120.95 mm |
ARCH Venture Fund X | 12.26 mm | $0.00 |
ARK Investment Management | 5.99 mm | $41.95 bn |
Vanguard | 5.80 mm | $40.61 bn |
Newpath Partners | 5.31 mm | $0.00 |
FMR | 3.92 mm | $27.47 bn |
BLK Blackrock | 3.76 mm | $26.29 bn |
CMTDF Sumitomo Mitsui Trust | 3.36 mm | $23.55 bn |
Nikko Asset Management Americas | 3.36 mm | $23.52 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jun 24 | Schenkein David P | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
12 Jun 24 | Nelsen Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
12 Jun 24 | Kelly Michael Aaron | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
12 Jun 24 | Foster-Cheek Kaye I | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
12 Jun 24 | Wendy Chung | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 45,000 | 345.60 k | 45,000 |
News
HC Wainwright & Co. Initiates Coverage On Prime Medicine with Buy Rating, Announces Price Target of $10
20 May 24
Citigroup Upgrades Prime Medicine to Buy, Announces $10 Price Target
16 May 24
JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $15
13 May 24
Prime Medicine Q1 2024 GAAP EPS $(0.44) Beats $(0.47) Estimate
10 May 24
Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease
8 May 24
Press releases
Prime Medicine to Present at Upcoming Investor Conferences
30 May 24
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
13 May 24
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
1 May 24
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
29 Apr 24